Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), David K. Shay(National Center for Emerging and Zoonotic Infectious Diseases), Lauri E. Markowitz(Centers for Disease Control and Prevention), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Michael M. McNeil(Centers for Disease Control and Prevention), Ruiling Liu(Nanjing Agricultural University), Tanya R. Myers(Centers for Disease Control and Prevention), Anne M. Hause(Centers for Disease Control and Prevention), Penelope Strid(Centers for Disease Control and Prevention), Winston E. Abara(Centers for Disease Control and Prevention), Bicheng Zhang(Centers for Disease Control and Prevention), John R. Su(National Center for Emerging and Zoonotic Infectious Diseases), Julianne Gee, Paige Marquez(Centers for Disease Control and Prevention)
Cited by 183
Related Papers
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k